Vertex Pharmaceuticals (VRTX)
Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on Vertex Pharmaceuticals today and set a price target of $500.00. The company’s shares closed last Friday at $496.07.
According to TipRanks.com, Matteis is a 5-star analyst with an average return of 18.0% and a 52.9% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Neumora Therapeutics, Inc., Lexeo Therapeutics, Inc., and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vertex Pharmaceuticals with a $559.27 average price target, a 14.8% upside from current levels. In a report issued on August 4, TipRanks – Anthropic also downgraded the stock to Hold with a $513.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
